Name: FHD-609 **Cat#:** EX-A7353

Target: Epigenetic Reader Domain
Pathway: Epigenetics

Chemical Structure:



Chemical Name	(S)-3-(6-(7-((1-(4-(6-(azetidin-1-yl)-2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-yl)-2,6-dimethoxybenzyl)piperidin-4-yl)methyl)-2,7-diazaspiro[3.5]nonan-2-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Molecular Weight	828.9975	Storage	Powder 3 years -20°C; 2 years 4°C 6 months -80°C in solvent Away from light
Formula	C47H56N8O6		
CAS No.	2676211-64-4	Synonyms	FHD609

Solubility (25°C) *	In vitro	DMSO	>50mg/mL
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)	In Vivo Add each solvent one by one: 1. 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (3.02mM); Clear solution 2. 10% DMSO >> 90% (20% SBE-β-CD in saline)	

		Solubility: ≥ 2.5 mg/mL (3.02mM); Clear solution

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	1.2063 mL	6.0314 mL	12.0627 mL
5 mM	0.2413 mL	1.2063 mL	2.4125 mL
10 mM	0.1206 mL	0.6031 mL	1.2063 mL

DMSO :

*The above data is based on the product molecular weight 829.00.

Biological Activities:

Description	FHD-609 is a potent, selective protein degrader of BRD9 (bromodomain-containing protein 9), a subunit of ncBAF (non-canonical BAF complex).
IC_{50} & Target	BRD9

References	[1]. Hescheler, Daniel Alexander et al. "Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options." Cancers vol. 14,11 2721. 31 May. 2022 [2]. Rechberger JS, et al. Atypical teratoid rhabdoid tumor (ATRT): disease mechanisms and potential drug targets. Expert Opin Ther Targets. 2022 Mar;26(3):187-192.